Therapy Area topics
Cardiovascular
Go or no go? Argenx's December showdown
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
Novo’s $3.3bn GalXC quest
The usually conservative group spends big on Dicerna – but others might be interested too.
Central Nervous System
Neurocrine gets selective in schizophrenia
The group’s deal with Sosei will see it compete with Karuna and Cerevel.
EU steers clear of Aduhelm as a bigger headache threatens
Aduhelm’s likely EU rejection comes amid a key senior executive departure and federal inquiry, and the drug now faces a crucial Medicare decision.
Diabetes
Novo’s $3.3bn GalXC quest
The usually conservative group spends big on Dicerna – but others might be interested too.
Digital Health
Medtech venture funding hits new heights
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
Respiratory
What Novartis could buy with its windfall
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
Boehringer takes a different approach in cystic fibrosis gene therapy
Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.
Various
Go or no go? Argenx's December showdown
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
